<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:regn="http://regeneron.com/20220601">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_regn_regeneron.com_20220601 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20220601_20220601 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000872589 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:EntityCentralIndexKey">0000872589</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="regn-20220601.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-06-01to2022-06-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90B_edei--DocumentType_c20220601__20220601_zQMKWArruc65"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
June 2, 2022 (<span id="xdx_907_edei--DocumentPeriodEndDate_c20220601__20220601_zuRbqcH7jOv8"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 1, 2022</ix:nonNumeric></span>)</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityRegistrantName_c20220601__20220601_z7IPxYSOwRij"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:EntityRegistrantName">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20220601__20220601_z3tVil7QQjf1"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(State or other
jurisdiction of incorporation)</b></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 51%"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityFileNumber_c20220601__20220601_z1MUZDwEUo5d"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:EntityFileNumber">000-19034</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 48%"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20220601__20220601_zZRZcL9Z5SY"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:EntityTaxIdentificationNumber">13-3444607</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(Commission</b></span></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>File Number)</b></span></p></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(I.R.S.
                                    Employer</b></span></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Identification
        No.)</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></td></tr>
<tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20220601__20220601_z6xGwWwrS8xd"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:EntityAddressAddressLine1">777 Old Saw Mill River Road</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressCityOrTown_c20220601__20220601_zgFYTsP5UYMf"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:EntityAddressCityOrTown">Tarrytown</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20220601__20220601_z5vxNgQ0RUT3"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: bottom; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20220601__20220601_zlknbrbsR82h"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:EntityAddressPostalZipCode">10591-6707</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code: (<span id="xdx_90C_edei--CityAreaCode_c20220601__20220601_zV3d6d8lASn4"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:CityAreaCode">914</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20220601__20220601_zU1mmhBOJAK6"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:LocalPhoneNumber">847-7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_909_edei--WrittenCommunications_c20220601__20220601_zkK1lyiYyQp4"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90E_edei--SolicitingMaterial_c20220601__20220601_zhCT7Ys2udX3"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20220601__20220601_z9nipqNTOG5b"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20220601__20220601_zLh53opFIRx1"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: black 1pt solid; font-size: 10pt; border-image: none; width: 42%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 20%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 38%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90D_edei--Security12bTitle_c20220601__20220601_zIVipA65L623"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:Security12bTitle">Common Stock &#8211; par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20220601__20220601_zASySJinaUGj"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" name="dei:TradingSymbol">REGN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_904_edei--SecurityExchangeName_c20220601__20220601_zht4LqnySbll"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20220601__20220601_z9Lo91HTJNDa"><ix:nonNumeric contextRef="From2022-06-01to2022-06-01" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01.&#160; Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>A&amp;R
IO License and Collaboration Agreement</i></span>. On June 1, 2022, Regeneron Pharmaceuticals,&#160;Inc., a New York corporation (&#8220;<span style="text-decoration: underline">Regeneron</span>&#8221;
or the &#8220;<span style="text-decoration: underline">Company</span>&#8221;), and Sanofi Biotechnology SAS, a soci&#233;t&#233; par actions simplif&#233;e organized under the
laws of France (&#8220;<span style="text-decoration: underline">Sanofi Biotechnology</span>&#8221;), entered into the Amended and Restated Immuno-Oncology License and Collaboration
Agreement (the &#8220;<span style="text-decoration: underline">A&amp;R IO LCA</span>&#8221;), which amends the Immuno-Oncology License and Collaboration Agreement, dated as of
July&#160;1, 2015 and executed as of July&#160;27, 2015 (as amended), by and between the Company and Sanofi Biotechnology (the &#8220;<span style="text-decoration: underline">Original
IO LCA</span>&#8221;). The A&amp;R IO LCA is subject to and will become effective on the first day of the first month following receipt
of all necessary authorizations and expiration of all necessary waiting periods applicable to the consummation of the A&amp;R IO LCA
(such date, the &#8220;<span style="text-decoration: underline">A&amp;R Effective Date</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Original IO LCA provides for Regeneron and
Sanofi Biotechnology to collaborate on the development and commercialization of certain immuno-oncology products, including Libtayo<sup>&#174;</sup>
(cemiplimab). From and after the A&amp;R Effective Date, Regeneron will have the sole right to develop and commercialize Libtayo worldwide
and no other products will be subject to the A&amp;R IO LCA; and Regeneron will also obtain a license under certain intellectual property
rights of Sanofi Biotechnology to develop and commercialize Libtayo worldwide and Sanofi Biotechnology will transfer to Regeneron certain
regulatory, promotional, and other rights relating to the commercialization of Libtayo outside the United States. The parties have also
entered into a transition services agreement, a transitional distribution agreement, and a manufacturing services agreement, pursuant
to which, during certain transitional periods, Sanofi Biotechnology will perform for Regeneron certain transition, distribution, and manufacturing
services, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the A&amp;R IO LCA, the quarterly period ended March&#160;31, 2022 is the last quarter for which Sanofi Biotechnology and Regeneron share
net profits and losses for Libtayo under the Original IO LCA. From and after April&#160;1, 2022 (after giving effect to certain true-up
payments as set forth in the A&amp;R IO LCA), Regeneron will be entitled to all profits from Libtayo and will pay Sanofi Biotechnology
an 11% royalty on net product sales of Libtayo through March&#160;31, 2034. In addition, the A&amp;R IO LCA provides for the following
payments by Regeneron to Sanofi Biotechnology: (i)&#160;a $900 million upfront payment, payable within 10 business days after the A&amp;R
Effective Date; (ii)&#160;a $100 million development milestone payment upon the first marketing approval from the U.S. Food and Drug Administration
or the </span><span style="background-color: white">European Commission</span> of Libtayo in non-small cell lung cancer in combination
with chemotherapy; and (iii)&#160;sales milestone payments of up to $100 million in the aggregate upon achieving certain amounts of worldwide
net product sales of Libtayo in 2022 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the A&amp;R IO LCA, the amount of development
costs incurred under the Original IO LCA for which Regeneron is obligated to reimburse Sanofi Biotechnology is $35 million. Regeneron
will reimburse Sanofi Biotechnology for such development costs by paying Sanofi a 0.5% royalty on Regeneron&#8217;s net product sales
of Libtayo until Regeneron has reimbursed Sanofi Biotechnology for all such development costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fifth
Amendment to Antibody LCA.</i></span> On June 1, 2022, Regeneron, Sanofi Biotechnology, and Sanofi, a soci&#233;t&#233; anonyme organized
under the laws of France (&#8220;<span style="text-decoration: underline">Sanofi Parent</span>&#8221;), entered into the Fifth Amendment to Amended and Restated License and Collaboration
Agreement (the &#8220;<span style="text-decoration: underline">Fifth Amendment</span>&#8221;), which amends the Amended and Restated License and Collaboration Agreement, dated
as of November&#160;10, 2009 (as amended), by and between the Company, Sanofi Biotechnology (as successor in interest to Aventis Pharmaceuticals
Inc.) and Sanofi Parent (the &#8220;<span style="text-decoration: underline">Antibody LCA</span>&#8221;) and will become effective on the A&amp;R Effective Date. Pursuant to
the Fifth Amendment, the parties amended the Antibody LCA, among other matters, to, from and after April&#160;1, 2022, increase from
10% to 20% the percentage of Regeneron&#8217;s share of profits used to reimburse Sanofi Biotechnology for the remaining development
costs incurred under the Antibody LCA subject to reimbursement by Regeneron.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the A&amp;R IO LCA and the Fifth Amendment is qualified in its entirety by reference to the full text of the
A&amp;R IO LCA and the Fifth Amendment, a copy of each of which will be filed with the U.S. Securities and Exchange Commission as an exhibit
to the Quarterly Report on Form&#160;10-Q to be filed by the Company for the quarterly period ending June&#160;30, 2022</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b><i>Note Regarding Forward-Looking
Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>This Current Report on Form&#160;8-K (this &#8220;<span style="text-decoration: underline">Report</span>&#8221;)
includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron
Pharmaceuticals,&#160;Inc. (&#8220;Regeneron&#8221; or the &#8220;Company&#8221;), and actual events or results may differ materially
from these forward-looking statements. Words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
 &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; variations of such words, and similar expressions are intended to identify
such forward-looking statements, although not all forward-looking statements contain these identifying words. Risks that may cause these
forward-looking statements to be inaccurate include, among others: risks related to the satisfaction or waiver of the conditions to closing
the proposed restructuring (the &#8220;<span style="text-decoration: underline">Proposed Restructuring</span>&#8221;) of the Company&#8217;s Immuno-oncology Collaboration with
Sanofi related to Libtayo<sup>&#174;</sup> (cemiplimab) (including the failure to obtain necessary regulatory approvals) in the anticipated
timeframe or at all; risks related to the Company&#8217;s ability to realize the anticipated benefits of the Proposed Restructuring, including
the possibility that the expected benefits from the Proposed Restructuring will not be realized or will not be realized within the expected
time period; and the impact of the Proposed Restructuring on Regeneron&#8217;s business, operating results, and financial condition, as
well as effects of this announcement or the consummation of the Proposed Restructuring on the market price of the Company&#8217;s common
stock. Any forward-looking statements are made based on management&#8217;s current beliefs and judgment, and the reader is cautioned not
to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise)
any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information,
future events, or otherwise.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; font-size: 10pt; width: 50%">&#160;</td>
    <td style="font-size: 10pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGENERON PHARMACEUTICALS,&#160;INC.</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Joseph J. LaRosa</p></td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph J. LaRosa</span></td></tr>
  <tr>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President, General Counsel and Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date:
June 2, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk38Ae2bFhWxihQRX2O7SrDNlk38O5K3NLaIy8KyzHwzQnTEkhamRIbjLEthj1Vdao+Q4RkZbY7BkazWMYSb4cU4z9r65v2BCQUGAzPqylMehMZ6Nw6LGOS4J1VPTUAOYzWA6UZEXz0hezYFWm90CdoWsGOq2aDX/GoT9vpJlqpXU3VAdoZsDKorW/kNfan6sKW7fhBfHaRpIqJOM5FYMt3qb83NeapgXmIVulyL/jf6ADFtSWw= -->
